Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Yuji EsoHaruhiko TakedaKojiro TauraAtsushi TakaiKen TakahashiHiroshi SenoPublished in: Current oncology (Toronto, Ont.) (2021)
The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC.
Keyphrases